SCHEMBL14441002

SCHEMBL14441002

CN(CO)c1c2c(c(O)c(=O)n1C)C(=O)N(Cc1ccc(F)cc1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
HTT P42858 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
AKR1B1 P15121 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
POLB P06746 3/20 0.36
WDR5 P61964 2/20 0.35
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
NPC1 O15118 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479091 0.87 AKR1B1 (0.41) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL13675039 0.86 LMNA (0.39) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL13672777 0.82 AKR1B1 (0.41) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL13672778 0.80 AKR1B1 (0.43) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4479556 0.79 CENPE (0.44) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL14441029 0.79 AKR1B1 (0.36) AKR1B1WDR5MAPK1
SCHEMBL4473972 0.79 AKR1B1 (0.41) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4490682 0.78 CENPE (0.40) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4487792 0.76 THRB (0.46) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4495602 0.76 AKR1B1 (0.40) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H LMNA 4273/4885SMN1; SMN2 4492/4885HTT 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.